Skip to main navigation Skip to search Skip to main content

Drug Development for Target Ribosomal Protein rpL35/uL29 for Repair of LAMB3R635X in Rare Skin Disease Epidermolysis Bullosa

  • Adriana Rathner
  • , Petr Rathner
  • , Andreas Friedrich
  • , Michael Wießner
  • , Christian Manuel Kitzler
  • , Jan Schernthaner
  • , Thomas Karl
  • , Jan Krauß
  • , Friedrich Lottspeich
  • , Werner Mewes
  • , Helmut Hintner
  • , Johann W Bauer
  • , Michael Breitenbach
  • , Norbert Müller
  • , Hannelore Breitenbach-Koller
  • , Jörg von Hagen

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)167-182
Number of pages16
JournalSkin Pharmacology and Physiology
Volume34
Issue number4
DOIs
Publication statusPublished - 2021

Bibliographical note

© 2021 S. Karger AG, Basel.

Keywords

  • Artesunate/chemistry
  • Atazanavir Sulfate/chemistry
  • Cell Adhesion Molecules/genetics
  • Epidermolysis Bullosa, Junctional/genetics
  • Humans
  • Molecular Docking Simulation
  • Protein Binding/physiology
  • RNA, Messenger/metabolism
  • Ribosomal Proteins/metabolism
  • Skin/pathology
  • Skin Physiological Phenomena
  • Mutations
  • Epidermolysis bullosa
  • Drug development
  • Skin models
  • Premature termination codon
  • Ribosomal protein L35
  • mutations

Fields of Science and Technology Classification 2012

  • 302 Clinical Medicine
  • 304 Medical Biotechnology
  • 106 Biology

Cite this